UNSPSC 51422359: Paramethasone disodium phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28FO8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41I31208JK, chemically known as pregna-1,4-diene-3,20-dione, 6-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as paramethasone disodium phosphate, which bears US NIH Compound Identifier 16509.

European Medicines Agency schedules paramethasone disodium phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09614MIG. Most nations, for tariff purposes, schedule paramethasone disodium phosphate under HS 29372200. SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)C)F.[NA+].[NA+].

UNSPSC 51422359 Paramethasone disodium phosphate is a Commodity code that in recent state and local procurement practice diverges sharply from its nominal pharmaceutical scope. The single recent opportunity on record shows the code applied to procurement of naloxone and drug deactivation systems rather than the corticosteroid the code name describes. Seminole County, Florida posted an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The procurement framing—supporting community health initiatives and requiring electronic bid submission through the county's e-Procurement Portal—reflects typical county health department or emergency services purchasing, but the actual commodities do not align with the code's stated pharmaceutical specification. The mismatch between code taxonomy and sourced work suggests either a cataloging error in the county's procurement system or a broad assignment of health-related acquisitions to this code without regard to active ingredient or product class.

The code shows minimal recent activity in state and local procurement. Seminole County, Florida represents the only documented recent opportunity, with an IFB response deadline of July 26, 2023 (predating the current date by nearly three years). No additional issuing bodies, states, or procurement examples appear in recent records, and no geographic concentration pattern emerges from a single sourced opportunity. Bidders on the Seminole County IFB must comply with drug-free workplace certification, E-Verify requirements, and insurance provisions including workers' compensation and commercial general liability; the contract structure includes an initial two-year term with a one-year renewal option and a three-month probationary termination window. The procurement does not reference explicit set-asides for small business, minority business, women business, or other disadvantaged-enterprise preferences. Given the code's sparse recent activity and the clear misalignment between the nominal pharmaceutical specification and the actual commodities being procured, the code appears low-priority for active business development until clearer state and local procurement patterns emerge.